Health

Add as a preferred source on Google

Evotec Reports FDA Acceptance of Second Bristol Myers Squibb Drug Application

The unnamed cereblon E3 ligase modulator is expected to begin Phase 1 testing in 2027, Evotec said.

Updated 1 min read
Researchers enter a biotechnology laboratory campus in Toulouse, France, on an overcast morning. (AI-generated image / EconoTimes)
Researchers enter a biotechnology laboratory campus in Toulouse, France, on an overcast morning. (AI-generated image / EconoTimes)

Evotec said the U.S. Food and Drug Administration (FDA) accepted an application for a second drug candidate developed with Bristol Myers Squibb, advancing their protein-degradation partnership toward another clinical trial expected in 2027.

The candidate is a cereblon E3 ligase modulator, or CELMoD. Evotec did not disclose its name, intended disease or a planned trial start date.

The companies’ first candidate, BMS-986506, entered a Phase 1 trial in March 2026 for advanced clear cell renal cell carcinoma, Evotec said. The trial’s start triggered a $10 million milestone payment to Evotec. The company said acceptance of the first application in November 2025 triggered a separate $5 million payment.

The collaboration began in 2018 and expanded in 2022. Evotec says it brings multi-omics screening, AI-supported analytics and drug-design capabilities to the partnership, while Bristol Myers Squibb contributes its CELMoD library.

Evotec describes molecular glue degraders as compounds that bring a target protein into contact with an E3 ubiquitin ligase, prompting the target’s degradation. CELMoDs induce interactions involving cereblon, the company said.

Evotec Chief Scientific Officer Joanna Holbrook said the second candidate’s progress to application acceptance demonstrated the repeatability and productivity of the company’s discovery platform.

Evotec expects the candidate to enter a Phase 1 trial in 2027, but has not provided a more specific date or identified a subsequent regulatory milestone.

Related articles

View all